{"name":"QurAlis Corporation","slug":"quralis-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"QRL-101 Dose A","genericName":"QRL-101 Dose A","slug":"qrl-101-dose-a","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"QRL-101 Dose A","genericName":"QRL-101 Dose A","slug":"qrl-101-dose-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRHJtakxvdkRYZ3J2azgyVWJiMVJpdDNZSFBQbEFfakVCcjZ0dUsydlVOMTlxa2pFdUdVengtendsdmJ2UG9nYzB5aVBJc1pYMmJwbnVkeTdlZ0xEMDRVVVBrYnFrN1lsNmo4VGlKdkdCSnV0c3VkdzlmRFluXzgtbmVNQURBNFpKa00tZDlWeXBod3hLR3ExTmpLbUxRTGFkMThDV0FmMk54VHJpeEhWbzRoSEhXVUlsYi1Ca2QyV3dPbWxvV0ZqMGFqbnN4Rk5Wd3N6ZUZ0dVR1MGpMdzF6eFhLN1l2a1MxbnFock1VU0ZMY0RHRTBHUmVB?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight - Barchart.com","headline":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPWUV4b3RTRE0wWFJ3R1IyQlpwUUFCWXBfTUNpSGNzMS1CMkRqT3RncXZZYjdDSDktSVpRNkg2bTRWYmRhTlNnRFdFTXBmSWhaVU1UMF93UGxsRHVNSkZBaVpNbWpVQ1RRVnBKblczSWx6OFRLTngzc2ZHLWZzR3Fja0RqRW00bzR4d2hUT2g1S3d0bkdWZGN6eHZwS2wzQTFzVDRKTFBMcUhabXdNQkg1aS1pZkhtdmJHTTV5N082ejhVQS1XdVZPdkhRZmo1aFh6QUtVbl83eEdhSmNDYTZSLXc2bGc0b3lLaWp0ay1zQ05vN3M?oc=5","date":"2026-02-24","type":"trial","source":"Citeline News & Insights","summary":"QurAlis In Fundraising Mode After Potentially Value-Creating Readout In ALS - Citeline News & Insights","headline":"QurAlis In Fundraising Mode After Potentially Value-Creating Readout In ALS - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQQVBKUFJIRkh3aU9KeHdPaEZpZ29kUEpGbGlEV3hJTmdRQjRFREJmbm5KcFJmdDdheWpyVVc0NWg0ZFltbVV2RXdvWkJmeHFpeElZeFB4VGcxTTE2SmhRTU5lckI3a293TERuT0NMbVlUTURhY0xJSDlzTEtHVklaSW1ueEpRNXpuTGk2YTgyenA2NVhXWjRVejd1UQ?oc=5","date":"2025-12-30","type":"trial","source":"The Pharma Letter","summary":"ALS results to propel QurAlis’ QRL-101 into Phase II - The Pharma Letter","headline":"ALS results to propel QurAlis’ QRL-101 into Phase II","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOcWlNVDh0bnpKUXVCRF93VWlzUkFWVzA4aWZfMW1hVkVYT0xaeDV0VVlaa3pSY1g0Wjk1azRYa0ZMaV9jLW9tTHVhWG00RGo2NjJlbjhKUzNYbURLNHZiNXFFLWt0cEVROVg0V25Rbk9FaWtyaldrVmpoU1diUzhDbzQ1eGg2Z0M5V0lvc0xfN09EOHJRWEZCZFNNdkxQYUdlSWhEMXZfSQ?oc=5","date":"2025-11-14","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Ovid eyes next chapter with CEO transition - Fierce Biotech","headline":"Chutes & Ladders—Ovid eyes next chapter with CEO transition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQZDV2Y1lTQTJzYm16ejZJZ1ZrQXpfU2ZLQnVIZU9wc1FDYkFaX2MyeERlTGdRb3FwZ2M5Um5BVUxKLVRsVUh2d2FwbXVCYl9xeHY1Zzk3TFZxb29sOVRIOUcwUVljYzFfcHNWSFRGV09GQkdqOUhTNXJaSURjUG11NDVPeGRrREFId2JjMzc3RFdLbVdnWF9pYUdQQWJmSEtUVThLcWdvUUhVZ2xCMXVvMlVGUFFmdFZuNV9kMmxTVmUzcm5Ibkk2ZGF6VXpjWE0?oc=5","date":"2025-11-10","type":"pipeline","source":"businesswire.com","summary":"QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer - businesswire.com","headline":"QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPbERub2pEU0diSDhxWmtmVUZwY3otQmVjS1N1YXp6RC1YLVN3dTRRTjBObWNkVHN6eFZacnVsYnIxY0ltaHlOSE9jYkpvOWlWenpSUllYb243T3BTR1czNXFnNWpKTy1mNVJic1p0MzBoUUlFZF9xMGVlUURORnp3WDNxLTA5c3RWQmRGLVhwNmJNeEFTWVE?oc=5","date":"2025-05-06","type":"regulatory","source":"BioSpace","summary":"Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal - BioSpace","headline":"Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNOGJ0clBGRUJFcUpyMnhHQTFuZ3hsdm14czQ0QUdmV0YtSUVqaFRfckN2Znc3SDFRY2VvZDgyUmREU0l0c19jeGtYV0dqVWRKSXFQc2Y0MmNXMklzXzY2WTFJLUZhZlR2WjlYR2ZZZnpSODBhRlIxQWFhNnFsRFVTVlIzTU9ycktfNWtv?oc=5","date":"2024-06-03","type":"deal","source":"BioPharma Dive","summary":"Eli Lilly adds ALS drug prospect with QurAlis deal - BioPharma Dive","headline":"Eli Lilly adds ALS drug prospect with QurAlis deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZmF0RjA2YjBTMlhiamVUbnFCWF9va1RrQkJIaWx0ZUlSWngtdUhabzFaS3RmSzdMVjNLbk1ibWdKSUtKTHJTXzZ3M2VMU19SaVRtcnNLTFJrNTFKQ2lwS0o2bFo3RFZzUTE4XzFKSmtGLTY2X2E4ZHFCSFA5aG5ycEVRczN0MVAzcHJlcTl6VEJ6NndVR2dHTXdIU1ZNZEp1cEVETm1FeU1fUQ?oc=5","date":"2024-06-03","type":"deal","source":"Contract Pharma","summary":"Lilly Licenses QurAlis’ ALS Precision Therapy for $45M Upfront - Contract Pharma","headline":"Lilly Licenses QurAlis’ ALS Precision Therapy for $45M Upfront","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPak1uWGhSb1dBM0ZnSTlBQUp2d1ZUdW1QNnNqRlN1dVZfTDQtSm02bUxMRkYzSVdNeTZWSW1Kd1J3OFFveTE1NGpJcVZGUGdpWFFReGxvajZsTFlRS0lLdUdpVExKdnNBdUlmTDNwVVJwSHNWSEZtRnVZSTlRWGJvUHg4NnRObHRPZGtNcTE0cGdhM3lndF9EUWpaSmNaYlVoSlhnQ3gtckVJMFgxX2c?oc=5","date":"2024-06-03","type":"deal","source":"Pharmaceutical Technology","summary":"Lilly strikes deal with QurAlis for preclinical ALS candidate - Pharmaceutical Technology","headline":"Lilly strikes deal with QurAlis for preclinical ALS candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQT0lhU2tVdERPZXlmaGRVVWhUU1NmbmVMVGRwV18ybzdQVG95VU85NzJnSFM1dWxpdjFGMFZHdEhvN0d5NFFPWExZeUxnRmoyZjE0aXlFLU1XZVg2X1VKR045UmVjVVFKZmxxeUVzaTE3d1RXUi1ZX2hXdDBiSmpucmtKbmJoWGtFUWZod1J0OHREMm8?oc=5","date":"2024-06-03","type":"deal","source":"BioWorld News","summary":"Quralis licenses QRL-204 to Lilly for up to $622M - BioWorld News","headline":"Quralis licenses QRL-204 to Lilly for up to $622M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOdXplRjVoSWhORllwaFZNTlBBZ1lrOWpXU3hrekRVNVE3VF9qMFY4Zk1kczlWYkhvSlBhMlhMOXZPTDI1Q29reG1yb0pmUlpZVkFLamFoaWJzemhHZ3JqMGhpRWw1MXB3ZnN6cEFBdWxfSnpzd1ZzMmRHZTM3endVVTFtMmxqTHhIWHNiZ3N3YmtydWJKRWhOLUVfYWtLMk15TU9PcTJ4Qlp2UzFlTkVPa3ZPMHlFYTFDREZJa0M1aFJtOXR5NkhzenRYV3dJdldLcl9KeWRhOE1uanNjUVE0YXZvX1JDenlsd0ZtYnMxeWFnMGUxd3poUllYV3ZGUW1fQ2ZmUjk2LTlmUERxaTJnYTJKUDJ3SjJSNjJhbXBHS2R1d1lM?oc=5","date":"2023-06-27","type":"trial","source":"prnewswire.com","summary":"QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies - prnewswire.com","headline":"QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Int","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQNXNwUkU0NENKcWNUaXVmMmtDdjRUZkpNaFJGUEhrYlVQMGhyc0R3dXJreUN1NVJzZlpDR1loXzFSel9DaTc1MllWQ2RNMEtWY19EYnlxSE5INklQZWdFSjBoSXZaN1NQaUVMRV84bG5nLUtMNVZxd1Fra3J0a1M0VjBDV1JtMjBhbWZQRWdVVnp2WE93WmNaZjR4OTh2NXYxdXRLOF94bGM2UnZLSGFVd0VDWldpbWFCOThwVS1NSC1pN20xcWhqZlVocThabTBHeTl3eXFHMzNwTDZlbzhPOWxVaVhoY1M3SjNtOEtJdVVKa0t3?oc=5","date":"2023-03-09","type":"pipeline","source":"prnewswire.com","summary":"QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases - prnewswire.com","headline":"QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}